On 13 April 2015, parties in the Questcor Pharmaceuticals, Inc. securities litigation (John Norton, Individually and on Behalf of All Others Similarly Situated vs. Questcor Pharmaceuticals, Inc.) reached an agreement to settle the case.  Plaintiffs alleged that Questcor made misstatements related to the effectiveness of, and prospects for, Questcor’s primary product H.P. Acthar Gel.  Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert reports and deposition testimony about market efficiency, loss causation, and the quantification of shareholder damages.


Additional information is available here.